
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …

Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …

